Novavax's COVID-19 shot gets approval for use in teenagers in South Korea

Aug. 12, 2022 9:47 AM ETNovavax, Inc. (NVAX)By: Anuron Mitra, SA News Editor1 Comment

Germany Begins Novavax Covid Vaccinations

Carsten Koall

  • Novavax (NASDAQ:NVAX) on Friday said its protein-based COVID-19 vaccine had received an expanded approval in South Korea for use in teenagers aged 12 to 17 years.
  • The U.S. company's partner, SK bioscience, got a post approval change application nod from the Korean Ministry of Food and Drug Safety for the COVID shot, Nuvaxovid, NVAX said in a statement.
  • "Today's approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option," said NVAX CEO Stanley Erck.
  • Nuvaxovid had already been given approval for use in teenagers aged 12 through 17 years in India, the European Union, Australia, Thailand and Japan, NVAX said.
  • NVAX stock earlier this week crashed 30% after reporting a sharp Q2 revenue miss and lowering its revenue guidance for the year.
  • Shares of Novavax (NVAX) were 4% higher at $41.94 in early trading.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.